Noradrenergic deficits contribute to apathy in Parkinson’s disease through the precision of expected outcomes
View ORCID ProfileFrank H. Hezemans, View ORCID ProfileNoham Wolpe, View ORCID ProfileClaire O’Callaghan, View ORCID ProfileRong Ye, View ORCID ProfileCatarina Rua, View ORCID ProfileP. Simon Jones, View ORCID ProfileAlexander G. Murley, View ORCID ProfileNegin Holland, View ORCID ProfileRalf Regenthal, View ORCID ProfileKamen A. Tsvetanov, View ORCID ProfileRoger A. Barker, View ORCID ProfileCaroline H. Williams-Gray, View ORCID ProfileTrevor W. Robbins, View ORCID ProfileLuca Passamonti, View ORCID ProfileJames B. Rowe
doi: https://doi.org/10.1101/2021.07.04.21259922
Frank H. Hezemans
1MRC Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom
2Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom
Noham Wolpe
1MRC Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom
3Department of Psychiatry, University of Cambridge, United Kingdom
4Department of Physical Therapy, Faculty of Medicine, Tel Aviv University, Israel
Claire O’Callaghan
3Department of Psychiatry, University of Cambridge, United Kingdom
5Brain and Mind Centre and School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Australia
Rong Ye
2Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom
Catarina Rua
2Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom
P. Simon Jones
2Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom
Alexander G. Murley
2Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom
Negin Holland
2Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom
Ralf Regenthal
6Division of Clinical Pharmacology, Rudolf-Boehm-Institute for Pharmacology and Toxicology, University of Leipzig, Germany
Kamen A. Tsvetanov
2Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom
7Department of Psychology, University of Cambridge, United Kingdom
Roger A. Barker
8John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, United Kingdom
9Wellcome – MRC Cambridge Stem Cell Institute, University of Cambridge, United Kingdom
Caroline H. Williams-Gray
8John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, United Kingdom
Trevor W. Robbins
7Department of Psychology, University of Cambridge, United Kingdom
10Behavioural and Clinical Neuroscience Institute, University of Cambridge, United Kingdom
Luca Passamonti
2Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom
11Istituto di Bioimmagini e Fisiologia Molecolare, Consiglio Nazionale delle Ricerche, Italy
James B. Rowe
1MRC Cognition and Brain Sciences Unit, University of Cambridge, United Kingdom
2Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, United Kingdom
Article usage
Posted July 06, 2021.
Noradrenergic deficits contribute to apathy in Parkinson’s disease through the precision of expected outcomes
Frank H. Hezemans, Noham Wolpe, Claire O’Callaghan, Rong Ye, Catarina Rua, P. Simon Jones, Alexander G. Murley, Negin Holland, Ralf Regenthal, Kamen A. Tsvetanov, Roger A. Barker, Caroline H. Williams-Gray, Trevor W. Robbins, Luca Passamonti, James B. Rowe
medRxiv 2021.07.04.21259922; doi: https://doi.org/10.1101/2021.07.04.21259922
Noradrenergic deficits contribute to apathy in Parkinson’s disease through the precision of expected outcomes
Frank H. Hezemans, Noham Wolpe, Claire O’Callaghan, Rong Ye, Catarina Rua, P. Simon Jones, Alexander G. Murley, Negin Holland, Ralf Regenthal, Kamen A. Tsvetanov, Roger A. Barker, Caroline H. Williams-Gray, Trevor W. Robbins, Luca Passamonti, James B. Rowe
medRxiv 2021.07.04.21259922; doi: https://doi.org/10.1101/2021.07.04.21259922
Subject Area
Subject Areas
- Addiction Medicine (400)
- Allergy and Immunology (711)
- Anesthesia (204)
- Cardiovascular Medicine (2957)
- Dermatology (250)
- Emergency Medicine (443)
- Epidemiology (12768)
- Forensic Medicine (12)
- Gastroenterology (829)
- Genetic and Genomic Medicine (4603)
- Geriatric Medicine (420)
- Health Economics (731)
- Health Informatics (2935)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (927)
- Medical Education (429)
- Medical Ethics (116)
- Nephrology (471)
- Neurology (4380)
- Nursing (237)
- Nutrition (640)
- Oncology (2281)
- Ophthalmology (648)
- Orthopedics (258)
- Otolaryngology (326)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (502)
- Pediatrics (1198)
- Primary Care Research (499)
- Public and Global Health (6967)
- Radiology and Imaging (1536)
- Respiratory Medicine (917)
- Rheumatology (442)
- Sports Medicine (385)
- Surgery (491)
- Toxicology (60)
- Transplantation (212)
- Urology (182)